Condensed Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (14,313,705)	$ (7,197,816)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		1,043
Research and development-acquired license, expensed	92,470	506,957
Stock-based compensation	1,322,821	737,746
Realized loss (gain) on marketable securities	41,808	1,177
Unrealized loss (gain) on marketable securities	176,974	(50,553)
Loss on foreign currency exchange	59,583
Changes in assets and liabilities:
Prepaid expenses	(5,420)	20,236
Accounts payable	535,340	(151,988)
Net cash used in operating activities	(12,090,129)	(6,133,198)
Cash flows from investing activities
Purchase of investments in joint venture		(410,000)
Purchase of research and development licenses	(116,970)	(167,457)
Purchase of marketable securities	(2,556,135)	(2,300,015)
Purchase of convertible promissory note in Isoprene		(50,000)
Sale of marketable securities	2,507,750	1,089,819
Net cash used in investing activities	(165,355)	(1,837,653)
Cash flows from financing activities
Proceeds from issuance common stock, common stock warrants and prefunded warrants, net of offering cost	13,407,632
Proceeds from issuance common stock and warrants, net of offering cost	4,427,501	4,193,756
Proceeds from issuance common stock, net of offering cost		4,475,000
Proceeds from exercise of warrants	359,513	56,250
Net cash provided by financing activities	18,194,646	8,725,006
Effect of exchange rate changes on cash and cash equivalents	(30,562)	(15,351)
Net change in cash	5,939,162	754,155
Cash, beginning of period	2,629,670	1,890,866
Cash, end of period	8,538,270	2,629,670
Non-cash investing and financing activities
Cancellation and retirement of common stock		$ 2